Field left the automated insulin delivery technology developer to pursue other opportunities, effective March 14, according to an SEC filing. As the company searches for Field’s successor, it tapped Amit Guliani to hold the post of interim CTO, effective immediately. Guliani currently serves as group VP, software engineering.
Insulet said Field will receive standard severance benefits under its amended and restated executive severance plan. The company also intends to enter into a consulting agreement with Field to facilitate a smooth transition.
Field joined Insulet in May 2019 after a stint as CTO at Thermo Fisher. Part of his initial remit was to find more engineers as the company moved forward in the development of its Omnipod 5 automated insulin delivery system. Field explained his journey to Insulet and the road to developing Omnipod 5 in a presentation at DeviceTalks West in Santa Clara, California, in 2023.
During his nearly 6 years at Insulet, Field helped bring the company’s latest-generation automated insulin delivery (AID) system, a small, discreet, tubeless, wearable patch pump, to market.
Omnipod 5 features SmartAdjust technology that uses CGM readings to predict where glucose will be 60 minutes into the future. Omnipod 5 then increases, decreases, or pauses insulin delivery based on the user’s desired and customized glucose target.
Insulet initially brought the system to market after it was FDA-cleared for ages two and up in the type 1 bracket in 2022. The company made Omnipod 5 the first and only such system cleared for type 1 and type 2 diabetes last August.
